AB0949 Serum 25-hydroxyvitamin d status in patient with psoriatic arthritis. (12th June 2018)

• Record Type: Journal Article
• Authors: Tsuji, S.; Hashimoto, J.; Noguchi, T.; Akita, S.; Yachi, K.; Ohshima, S.; Saeki, Y.; Higashiyama, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1599
• Page End: 1600
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.4822
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Vitamin D has been recognised not only in calcium metabolism and bone metabolism but also in the physiological activities of a wide variety of cells, and its deficiency is caused by fractures/falls, osteoporosis and other various disease risks have been reported. Objectives: To clarify vitamin D satisfaction status of patients with PsA, which is one of spondyloarthritis, by measuring serum 25OHD concentration. Methods: 180 patients with PsA satisfying CASPAR criteria during the visit to our hospital between August 2016 and June 2017, 125 males, averaging age 54.1 y.o., BMI average 24.2, mean disease duration of PsA and psoriasis were 8.1 years, 19.3 years, respectively. The type of psoriatic arthritis was 79 spondylitis type and 101 peripheral type. MTX was 51.7% as an agent for treating PsA, and the average dose was 8.3±3.1 mg/week. The number of biologics use was 37.2%. There were 9 cases of osteoporosis and 21 cases of osteopenia, 20 patients who were undergoing treatment for osteoporosis, and all patients were treated with activated VD3. 110 patients (61.1%) had active type VD3 paint applied to psoriasis eruption. The ACPA positive rate was 7.4%, the rheumatoid factor positive was 17.7%, and average CRP was 0.25±0.36 mg/dl. The test method for the serum 25OHD concentration was measured with the CLIA antibody method (SRL, Inc.). Regarding the judgment criteria of deficiency, although various discussions are in progress, "the index of serum 25OHD deficiency less than 20 ng/ml" prepared by the institute of medicine (IOM) in 2011 was used. As a study item, firstly, the degree of satisfaction of vitamin D using serum 25OHD concentration was determined. Second, it divided into VD deficient group and non-deficient group age, sex, disease duration, psoriatic arthritis type, blood biochemical test, presence of active VD administration, presence or absence of active type VD coating for skin, presence or absence of MTX · BIO, Osteoporosis · Percentage of osteopenia · The presence or absence of vulnerability fracture history was compared between both groups. Results: Mean serum 25OHD concentration in patients with PsA was 16.4±6.3 ng/ml and serum 25OHD deficiency was observed in 134cases (74.4%). Factors that showed significant differences between the two groups (VD deficient group/normal group) were age (54.4/59.0y.o. p=0.032), gender (female rate) 35.0%/11.9%: p=0.040, ACPA negative rate 97.0%/85.2%: p=0.010, serum MMP-3 (69.0/98.4 ng/ml p=0.030), active vitamin D top coating use rate for skin 54.0%/88.9%: p=0.001, Biologics treatment rate 49.3%/11.1%: p<0.001. Conclusions: 74.4% of patients with PsA had vitamin D deficiency. In the vitamin d-deficient group, low age, high female rate, ACPA negative, low serum MMP-3, VD coating low use rate for skin, biological product high usage rate were significant. Disclosure of Interest: None declared